| TITLE |
DATE |
PRICE |
| The Global Market for Equipment Used in Biotechnology Applications |
1/1/10 |
$4,850.00 |
|
|
| Life Sciences Funding - 2008 |
12/31/09 |
$6,500.00 |
|
|
| U.S. Epigenetics Markets |
12/31/09 |
$6,000.00 |
|
|
| MedImmune LLC - Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Applied Biosystems Group - Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Ceapro Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Pharming Group N.V. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Sangamo BioSciences, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| BioSyntech, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Ablynx NV - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Medarex, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Sigma-Aldrich Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Warnex Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Sernova Corp. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| United Therapeutics Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Vical Incorporated - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| CombiMatrix Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Interleukin Genetics Incorporated - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Helix BioPharma Corp. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Biogen Idec Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Celsion Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Smiths Group plc - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Clinical Data, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Affymetrix, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Baxter International Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Cardium Therapeutics, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Aastrom Biosciences, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Haemacure Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| BioTime, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Genzyme Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Seattle Genetics, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| ReNeuron Group plc - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Antisoma plc - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| XOMA Ltd. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Theratechnologies Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Pharmacyclics, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| DOR BioPharma, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| CytRx Corporation - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Cytokinetics, Inc - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Chelsea Therapeutics International, Ltd. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| BioCryst Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| ARQULE, INC - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Medivation, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Metabasis Therapeutics, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Curis, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| NeuroSearch AS - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| MultiCell Technologies, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Living Cell Technologies Limited - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Karo Bio - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Intercell AG - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
| Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
12/31/09 |
$125.00 |
|
|
